Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
Chaiho Jeong, Jinyoung Kim, Yejee Lim, Jeonghoon Ha, Moo Il Kang, Ki-Hyun Baek
J Bone Metab. 2021;28(4):317-323. Published online 2021 Nov 30 DOI: https://doi.org/10.11005/jbm.2021.28.4.317
|
Citations to this article as recorded by
Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions
Heenam Goel, Neil Binkley, Miranda Boggild, Wing P. Chan, William D. Leslie, Eugene McCloskey, Sarah L. Morgan, Barbara C. Silva, Angela M. Cheung
Journal of Clinical Densitometry.2024; 27(1): 101452. CrossRef Update on the utility of trabecular bone score (TBS) in clinical practice for the management of osteoporosis: a systematic review by the Egyptian Academy of Bone and Muscle Health
Yasser El Miedany, Walaa Elwakil, Mohammed Hassan Abu-Zaid, Safaa Mahran
Egyptian Rheumatology and Rehabilitation.2024;[Epub] CrossRef Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial
Chi Chiu Mok, Kar Li Chan, Sau Mei Tse, Sammy Pak Lam Chen, Kathryn Choon Beng Tan, Wai Han Ma
Journal of Internal Medicine.2024; 296(6): 481. CrossRef Trabecular Bone Score to Enhance Fracture Risk Prediction and Treatment Strategies in Osteoporosis
Guillaume Gatineau, Didier Hans, Karen Hind
Seminars in Musculoskeletal Radiology.2024; 28(05): 539. CrossRef Il ruolo del Trabecular Bone Score (TBS) nella gestione dell’osteoporosi primaria e secondaria
Fabio Bioletto, Massimo Procopio, Marco Barale
L'Endocrinologo.2024; 25(6): 634. CrossRef Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension
Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael McClung
Osteoporosis International.2023; 34(6): 1075. CrossRef Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease
Enisa Shevroja, Jean-Yves Reginster, Olivier Lamy, Nasser Al-Daghri, Manju Chandran, Anne-Laurence Demoux-Baiada, Lynn Kohlmeier, Marie-Paule Lecart, Daniel Messina, Bruno Muzzi Camargos, Juraj Payer, Sansin Tuzun, Nicola Veronese, Cyrus Cooper, Eugene V.
Osteoporosis International.2023; 34(9): 1501. CrossRef Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
Mingwei Hu, Yifan Zhang, Jianjun Guo, Cuicui Guo, Xue Yang, Xue Ma, Hao Xu, Shuai Xiang
Frontiers in Endocrinology.2023;[Epub] CrossRef Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
Namki Hong, Sungjae Shin, Seunghyun Lee, Yumie Rhee
Osteoporosis International.2023; 34(12): 2059. CrossRef Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)
E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez
SurgiColl.2023;[Epub] CrossRef The efficacy of denosumab in Korean male patients with osteoporosis
Chaiho Jeong, Jeonghoon Ha, Jinyoung Kim, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
The Korean Journal of Internal Medicine.2022; 37(5): 1011. CrossRef Update on trabecular bone score
Telma Palomo, Patricia Muszkat, Fernanda G. Weiler, Patricia Dreyer, Cynthia M. A. Brandão, Barbara C. Silva
Archives of Endocrinology and Metabolism.2022; 66(5): 694. CrossRef
|